Financial News Feed

Stronger Sell Today ACAD ranks #4050 as SELL CANDIDATE #4050 Weaker Sell

ACADIA Pharmaceuticals Inc. stock forecast

ACAD stock forecast

The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month....

Read more

ACAD earnings call for the period ending March 31, 2019....

Read more

Acadia (ACAD) delivered earnings and revenue surprises of -9.26% and 6.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

Read more

ACADIA Pharma misses by $0.07, beats on revenue
08:10pm, Wednesday, 01'st May 2019
ACADIA Pharma (ACAD): Q1 GAAP EPS of -$0.59 misses by $0.07. Revenue of $63M (+28.9% Y/Y) beats by $2.07M. Press Release...

Read more

ACADIA Pharma Q1 Earnings Preview
09:35pm, Tuesday, 30'th Apr 2019
No summary available....

Read more

No summary available....

Read more

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Read more

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s shares are under review with key ownership changing hands of late. As company earnings reports continue to roll in, investors will be watching to see whic...

Read more

Stock market investors might be taking note of recent trends. Many investors will be digging deep into the numbers to try and spot potential breakouts. Following the numbers for ACADIA Pharmaceuticals...

Read more

Keen investors are consistently searching for true bargains in the stock market. Finding these stocks can make the difference between a winning or losing portfolio. Shares of ACADIA Pharmaceuticals In...

Read more

We will be comparing the differences between ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Concert Pharmaceuticals Inc. (NASDAQ:CNCE) as far as risk, analyst recommendations, institutional ownership, ...

Read more

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) making news as their share price hit $26.64 at the end of the most recent trading day. Considering that price volatility is equivalent to risk, a commodity’...

Read more

ACADIA PHARMACEUTICALS INC files 8-K in a filing on Mon, April 01. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangemen...

Read more

Analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report $-0.54 EPS on May, 3.They anticipate $0.10 EPS change or 22.73% from last quarter's $-0.44 Impala Asset Management Llc decreased Roy...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank